Summary

Persistence Market Research has recently released a comprehensive research report on the global Neglected Tropical Diseases Diagnosis Market, offering an in depth evaluation of market dynamics, growth trends, opportunities, challenges, and the competitive landscape. The report is designed to provide healthcare stakeholders, diagnostic manufacturers, policymakers, and investors with actionable insights into the evolving diagnostic ecosystem for neglected tropical diseases, which continue to pose a significant public health burden across developing and underdeveloped regions.

Key Insights:

•Neglected Tropical Diseases Diagnosis Market Size (2025E): US$ 7,600.0 Mn
•Projected Market Value (2032F): US$ 10,204.8 Mn
•Global Market Growth Rate (CAGR 2025 to 2032): 4.3%

Neglected Tropical Diseases Diagnosis Market – Report Scope:

The neglected tropical diseases diagnosis market comprises a broad range of diagnostic products and services used for the detection, screening, and monitoring of diseases classified as neglected tropical diseases. These conditions primarily affect populations in low income and resource constrained regions, particularly in parts of Africa, Latin America, and South Asia. Accurate and early diagnosis plays a crucial role in disease control, treatment planning, and elimination initiatives. The market includes conventional diagnostic techniques as well as modern molecular and rapid point of care testing solutions. Increasing global awareness, expanded public health programs, and rising investments in infectious disease diagnostics are supporting steady market expansion over the forecast period.

Market Growth Drivers:

The growth of the global neglected tropical diseases diagnosis market is primarily driven by the rising prevalence of neglected tropical diseases across endemic regions and the growing emphasis on early detection to reduce disease transmission and long term complications. Increased funding from international health organizations, non governmental organizations, and government bodies for disease eradication programs has significantly strengthened diagnostic infrastructure in developing countries. Advancements in molecular and rapid diagnostic technologies have improved test accuracy, sensitivity, and turnaround times, thereby enhancing adoption across clinical laboratories and point of care settings. Additionally, global initiatives led by organizations such as the World Health Organization to eliminate neglected tropical diseases by strengthening surveillance and diagnostic capacity are further accelerating market growth.

Market Restraints:

Despite positive growth prospects, the neglected tropical diseases diagnosis market faces several challenges that may hinder its expansion. Limited healthcare infrastructure and inadequate access to diagnostic facilities in remote and rural areas continue to restrict timely disease detection. High costs associated with advanced molecular diagnostic techniques can limit adoption in low income regions where these diseases are most prevalent. A shortage of trained healthcare professionals and laboratory technicians further constrains effective diagnosis and disease management. In addition, inconsistent reimbursement frameworks and limited commercial incentives for manufacturers to invest heavily in neglected disease diagnostics may slow innovation and market penetration.

Market Opportunities:

The market presents substantial opportunities driven by the increasing demand for affordable, rapid, and point of care diagnostic solutions suitable for low resource settings. Technological innovation focused on portable, easy to use, and cost effective diagnostic platforms offers significant growth potential. Expansion of public private partnerships and collaborations between diagnostic companies and global health organizations can support product development and distribution in underserved regions. Emerging economies in South Asia, Africa, and Latin America offer untapped opportunities due to growing healthcare investments and rising disease awareness. Furthermore, integration of digital health tools and data driven disease surveillance systems is expected to enhance diagnostic reach and efficiency, creating new avenues for market expansion.

Key Questions Answered in the Report:

•What are the key factors driving the growth of the global neglected tropical diseases diagnosis market?
•Which disease segments and diagnostic methods are contributing most significantly to market revenue?
•How are advancements in molecular and point of care diagnostics influencing market dynamics?
•Which regions are expected to witness the fastest growth during the forecast period?
•Who are the leading players in the neglected tropical diseases diagnosis market and what strategies are they adopting?

Competitive Intelligence and Business Strategy:

Leading players in the neglected tropical diseases diagnosis market are focusing on expanding their diagnostic portfolios through innovation, strategic collaborations, and geographic expansion. Companies are investing in research and development to introduce rapid, sensitive, and affordable diagnostic solutions tailored for endemic regions. Partnerships with global health agencies and government bodies enable wider product deployment and strengthen market presence. Emphasis on localized manufacturing, distribution network expansion, and training programs for healthcare professionals is also helping companies enhance adoption and brand visibility in emerging markets.

Companies Covered in This Report:

•F. Hoffmann La Roche Ltd
•Thermo Fisher Scientific Inc.
•Abbott Laboratories
•Genome Diagnostics Pvt. Ltd.
•InBios International Inc.
•ZeptoMetrix
•Oscar Medicare Pvt Ltd
•Coris BioConcept
•Omega Diagnostics Group PLC
•DiaSys Diagnostic Systems GmbH
•Others

Market Segmentation

By Disease

•Dengue
•Rabies
•Yaws
•Chikungunya
•Leprosy
•Lymphatic Filariasis
•Buruli Ulcer
•Echinococcosis
•Taeniasis or Cysticercosis
•Dracunculiasis
•Foodborne Trematodiases
•Chagas Disease American Trypanosomiasis
•African Trypanosomiasis
•Soil transmitted Helminth Infections
•Onchocerciasis
•Scabies and Other Ectoparasites
•Schistosomiasis
•Snakebite Envenoming
•Leishmaniasis

By Diagnostic Method

•Conventional
•Molecular or Modern

By Service Type

•Centralized
•POC

By End use

•Clinical Laboratories
•Hospitals or Clinics
•Home Healthcare

By Region

•North America
•Europe
•East Asia
•South Asia and Oceania
•Latin America
•Middle East and Africa

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. Global Neglected Tropical Diseases Diagnosis Market Snapshot, 2025 and 2032
1.2. Market Opportunity Assessment, 2025-2032, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Key Trends
2.3. Macro-economic Factors
2.3.1. Public Health Spending and International Aid
2.3.2. Global Health Policy and Regulatory Frameworks
2.3.3. Geopolitical Stability and Infrastructure Development
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors – Relevance and Impact
3. Value Added Insights
3.1. Diagnostic Method Adoption Analysis
3.2. Regulatory Landscape
3.3. Value Chain Analysis
3.4. PESTLE Analysis
3.5. Porter’s Five Force Analysis
4. Price Analysis, 2024A
4.1. Key Highlights
4.2. Key Factors Impacting Service Costs
4.3. Pricing Analysis, By Diagnostic Method
5. Global Neglected Tropical Diseases Diagnosis Market Outlook
5.1. Key Highlights
5.1.1. Market Volume (Units) Projections
5.1.2. Market Size (US$ Mn) and Y-o-Y Growth
5.1.3. Absolute $ Opportunity
5.2. Market Size (US$ Mn) and Volume (Units) Analysis and Forecast
5.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2024
5.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2025-2032
5.3. Global Neglected Tropical Diseases Diagnosis Market Outlook: Disease
5.3.1. Introduction / Key Findings
5.3.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, By Disease, 2019-2024
5.3.3. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Disease, 2025-2032
5.3.3.1. Dengue
5.3.3.2. Rabies
5.3.3.3. Yaws
5.3.3.4. Chikungunya
5.3.3.5. Leprosy
5.3.3.6. Lymphatic Filariasis
5.3.3.7. Buruli Ulcer
5.3.3.8. Echinococcosis
5.3.3.9. Taeniasis/Cysticercosis
5.3.3.10. Dracunculiasis
5.3.3.11. Foodborne Trematodiases
5.3.3.12. Chagas Disease (American Trypanosomiasis)
5.3.3.13. African Trypanosomiasis
5.3.3.14. Soil-transmitted Helminth Infections
5.3.3.15. Onchocerciasis
5.3.3.16. Scabies and Other Ectoparasites
5.3.3.17. Schistosomiasis
5.3.3.18. Snakebite Envenoming
5.3.3.19. Leishmaniasis
5.3.4. Market Attractiveness Analysis: Disease
5.4. Global Neglected Tropical Diseases Diagnosis Market Outlook: Diagnostic Method
5.4.1. Introduction / Key Findings
5.4.2. Historical Market Size (US$ Mn) Analysis, By Diagnostic Method, 2019-2024
5.4.3. Current Market Size (US$ Mn) Analysis and Forecast, By Diagnostic Method, 2025-2032
5.4.3.1. Conventional
5.4.3.2. Molecular/Modern
5.4.4. Market Attractiveness Analysis: Diagnostic Method
5.5. Global Neglected Tropical Diseases Diagnosis Market Outlook: Service Type
5.5.1. Introduction / Key Findings
5.5.2. Historical Market Size (US$ Mn) Analysis, By Service Type, 2019-2024
5.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Service Type, 2025-2032
5.5.3.1. Centralized
5.5.3.2. POC
5.5.4. Market Attractiveness Analysis: Service Type
5.6. Global Neglected Tropical Diseases Diagnosis Market Outlook: End Use
5.6.1. Introduction / Key Findings
5.6.2. Historical Market Size (US$ Mn) Analysis, By End Use, 2019-2024
5.6.3. Current Market Size (US$ Mn) Analysis and Forecast, By End Use, 2025-2032
5.6.3.1. Clinical Laboratories
5.6.3.2. Hospitals/Clinics
5.6.3.3. Home Healthcare
5.6.4. Market Attractiveness Analysis: End Use
6. Global Neglected Tropical Diseases Diagnosis Market Outlook: Region
6.1. Key Highlights
6.2. Historical Market Size (US$ Mn) and Volume (Units) Analysis, By Region, 2019-2024
6.3. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Region, 2025-2032
6.3.1. North America
6.3.2. Europe
6.3.3. East Asia
6.3.4. South Asia and Oceania
6.3.5. Latin America
6.3.6. Middle East & Africa
6.4. Market Attractiveness Analysis: Region
7. North America Neglected Tropical Diseases Diagnosis Market Outlook
7.1. Key Highlights
7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
7.2.1. By Country
7.2.2. By Disease
7.2.3. By Diagnostic Method
7.2.4. By Service Type
7.2.5. By End Use
7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
7.3.1. U.S.
7.3.2. Canada
7.4. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Disease, 2025-2032
7.4.1. Dengue
7.4.2. Rabies
7.4.3. Yaws
7.4.4. Chikungunya
7.4.5. Leprosy
7.4.6. Lymphatic Filariasis
7.4.7. Buruli Ulcer
7.4.8. Echinococcosis
7.4.9. Taeniasis/Cysticercosis
7.4.10. Dracunculiasis
7.4.11. Foodborne Trematodiases
7.4.12. Chagas Disease (American Trypanosomiasis)
7.4.13. African Trypanosomiasis
7.4.14. Soil-transmitted Helminth Infections
7.4.15. Onchocerciasis
7.4.16. Scabies and Other Ectoparasites
7.4.17. Schistosomiasis
7.4.18. Snakebite Envenoming
7.4.19. Leishmaniasis
7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Diagnostic Method, 2025-2032
7.5.1. Conventional
7.5.2. Molecular/Modern
7.6. Current Market Size (US$ Mn) Analysis and Forecast, By Service Type, 2025-2032
7.6.1. Centralized
7.6.2. POC
7.7. Current Market Size (US$ Mn) Analysis and Forecast, By End Use, 2025-2032
7.7.1. Clinical Laboratories
7.7.2. Hospitals/Clinics
7.7.3. Home Healthcare
7.8. Market Attractiveness Analysis
8. Europe Neglected Tropical Diseases Diagnosis Market Outlook
8.1. Key Highlights
8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
8.2.1. By Country
8.2.2. By Disease
8.2.3. By Diagnostic Method
8.2.4. By Service Type
8.2.5. By End Use
8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
8.3.1. Germany
8.3.2. France
8.3.3. U.K.
8.3.4. Italy
8.3.5. Spain
8.3.6. Russia
8.3.7. Turkey
8.3.8. Rest of Europe
8.4. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Disease, 2025-2032
8.4.1. Dengue
8.4.2. Rabies
8.4.3. Yaws
8.4.4. Chikungunya
8.4.5. Leprosy
8.4.6. Lymphatic Filariasis
8.4.7. Buruli Ulcer
8.4.8. Echinococcosis
8.4.9. Taeniasis/Cysticercosis
8.4.10. Dracunculiasis
8.4.11. Foodborne Trematodiases
8.4.12. Chagas Disease (American Trypanosomiasis)
8.4.13. African Trypanosomiasis
8.4.14. Soil-transmitted Helminth Infections
8.4.15. Onchocerciasis
8.4.16. Scabies and Other Ectoparasites
8.4.17. Schistosomiasis
8.4.18. Snakebite Envenoming
8.4.19. Leishmaniasis
8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Diagnostic Method, 2025-2032
8.5.1. Conventional
8.5.2. Molecular/Modern
8.6. Current Market Size (US$ Mn) Analysis and Forecast, By Service Type, 2025-2032
8.6.1. Centralized
8.6.2. POC
8.7. Current Market Size (US$ Mn) Analysis and Forecast, By End Use, 2025-2032
8.7.1. Clinical Laboratories
8.7.2. Hospitals/Clinics
8.7.3. Home Healthcare
8.8. Market Attractiveness Analysis
9. East Asia Neglected Tropical Diseases Diagnosis Market Outlook
9.1. Key Highlights
9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
9.2.1. By Country
9.2.2. By Disease
9.2.3. By Diagnostic Method
9.2.4. By Service Type
9.2.5. By End Use
9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
9.3.1. China
9.3.2. Japan
9.3.3. South Korea
9.4. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Disease, 2025-2032
9.4.1. Dengue
9.4.2. Rabies
9.4.3. Yaws
9.4.4. Chikungunya
9.4.5. Leprosy
9.4.6. Lymphatic Filariasis
9.4.7. Buruli Ulcer
9.4.8. Echinococcosis
9.4.9. Taeniasis/Cysticercosis
9.4.10. Dracunculiasis
9.4.11. Foodborne Trematodiases
9.4.12. Chagas Disease (American Trypanosomiasis)
9.4.13. African Trypanosomiasis
9.4.14. Soil-transmitted Helminth Infections
9.4.15. Onchocerciasis
9.4.16. Scabies and Other Ectoparasites
9.4.17. Schistosomiasis
9.4.18. Snakebite Envenoming
9.4.19. Leishmaniasis
9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Diagnostic Method, 2025-2032
9.5.1. Conventional
9.5.2. Molecular/Modern
9.6. Current Market Size (US$ Mn) Analysis and Forecast, By Service Type, 2025-2032
9.6.1. Centralized
9.6.2. POC
9.7. Current Market Size (US$ Mn) Analysis and Forecast, By End Use, 2025-2032
9.7.1. Clinical Laboratories
9.7.2. Hospitals/Clinics
9.7.3. Home Healthcare
9.8. Market Attractiveness Analysis
10. South Asia & Oceania Neglected Tropical Diseases Diagnosis Market Outlook
10.1. Key Highlights
10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
10.2.1. By Country
10.2.2. By Disease
10.2.3. By Diagnostic Method
10.2.4. By Service Type
10.2.5. By End Use
10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
10.3.1. India
10.3.2. Southeast Asia
10.3.3. ANZ
10.3.4. Rest of South Asia & Oceania
10.4. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Disease, 2025-2032
10.4.1. Dengue
10.4.2. Rabies
10.4.3. Yaws
10.4.4. Chikungunya
10.4.5. Leprosy
10.4.6. Lymphatic Filariasis
10.4.7. Buruli Ulcer
10.4.8. Echinococcosis
10.4.9. Taeniasis/Cysticercosis
10.4.10. Dracunculiasis
10.4.11. Foodborne Trematodiases
10.4.12. Chagas Disease (American Trypanosomiasis)
10.4.13. African Trypanosomiasis
10.4.14. Soil-transmitted Helminth Infections
10.4.15. Onchocerciasis
10.4.16. Scabies and Other Ectoparasites
10.4.17. Schistosomiasis
10.4.18. Snakebite Envenoming
10.4.19. Leishmaniasis
10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Diagnostic Method, 2025-2032
10.5.1. Conventional
10.5.2. Molecular/Modern
10.6. Current Market Size (US$ Mn) Analysis and Forecast, By Service Type, 2025-2032
10.6.1. Centralized
10.6.2. POC
10.7. Current Market Size (US$ Mn) Analysis and Forecast, By End Use, 2025-2032
10.7.1. Clinical Laboratories
10.7.2. Hospitals/Clinics
10.7.3. Home Healthcare
10.8. Market Attractiveness Analysis
11. Latin America Neglected Tropical Diseases Diagnosis Market Outlook
11.1. Key Highlights
11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
11.2.1. By Country
11.2.2. By Disease
11.2.3. By Diagnostic Method
11.2.4. By Service Type
11.2.5. By End Use
11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
11.3.1. Brazil
11.3.2. Mexico
11.3.3. Rest of Latin America
11.4. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Disease, 2025-2032
11.4.1. Dengue
11.4.2. Rabies
11.4.3. Yaws
11.4.4. Chikungunya
11.4.5. Leprosy
11.4.6. Lymphatic Filariasis
11.4.7. Buruli Ulcer
11.4.8. Echinococcosis
11.4.9. Taeniasis/Cysticercosis
11.4.10. Dracunculiasis
11.4.11. Foodborne Trematodiases
11.4.12. Chagas Disease (American Trypanosomiasis)
11.4.13. African Trypanosomiasis
11.4.14. Soil-transmitted Helminth Infections
11.4.15. Onchocerciasis
11.4.16. Scabies and Other Ectoparasites
11.4.17. Schistosomiasis
11.4.18. Snakebite Envenoming
11.4.19. Leishmaniasis
11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Diagnostic Method, 2025-2032
11.5.1. Conventional
11.5.2. Molecular/Modern
11.6. Current Market Size (US$ Mn) Analysis and Forecast, By Service Type, 2025-2032
11.6.1. Centralized
11.6.2. POC
11.7. Current Market Size (US$ Mn) Analysis and Forecast, By End Use, 2025-2032
11.7.1. Clinical Laboratories
11.7.2. Hospitals/Clinics
11.7.3. Home Healthcare
11.8. Market Attractiveness Analysis
12. Middle East & Africa Neglected Tropical Diseases Diagnosis Market Outlook
12.1. Key Highlights
12.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2024
12.2.1. By Country
12.2.2. By Disease
12.2.3. By Diagnostic Method
12.2.4. By Service Type
12.2.5. By End Use
12.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2025-2032
12.3.1. GCC Countries
12.3.2. Egypt
12.3.3. South Africa
12.3.4. Northern Africa
12.3.5. Rest of Middle East & Africa
12.4. Current Market Size (US$ Mn) and Volume (Units) Analysis and Forecast, By Disease, 2025-2032
12.4.1. Dengue
12.4.2. Rabies
12.4.3. Yaws
12.4.4. Chikungunya
12.4.5. Leprosy
12.4.6. Lymphatic Filariasis
12.4.7. Buruli Ulcer
12.4.8. Echinococcosis
12.4.9. Taeniasis/Cysticercosis
12.4.10. Dracunculiasis
12.4.11. Foodborne Trematodiases
12.4.12. Chagas Disease (American Trypanosomiasis)
12.4.13. African Trypanosomiasis
12.4.14. Soil-transmitted Helminth Infections
12.4.15. Onchocerciasis
12.4.16. Scabies and Other Ectoparasites
12.4.17. Schistosomiasis
12.4.18. Snakebite Envenoming
12.4.19. Leishmaniasis
12.5. Current Market Size (US$ Mn) Analysis and Forecast, By Diagnostic Method, 2025-2032
12.5.1. Conventional
12.5.2. Molecular/Modern
12.6. Current Market Size (US$ Mn) Analysis and Forecast, By Service Type, 2025-2032
12.6.1. Centralized
12.6.2. POC
12.7. Current Market Size (US$ Mn) Analysis and Forecast, By End Use, 2025-2032
12.7.1. Clinical Laboratories
12.7.2. Hospitals/Clinics
12.7.3. Home Healthcare
12.8. Market Attractiveness Analysis
13. Competition Landscape
13.1. Market Share Analysis, 2024
13.2. Market Structure
13.2.1. Competition Intensity Mapping By Market
13.2.2. Competition Dashboard
13.3. Company Profiles (Details – Overview, Financials, Strategy, Recent Developments)
13.3.1. F. Hoffmann-La Roche Ltd
13.3.1.1. Overview
13.3.1.2. Segments and Diseases
13.3.1.3. Key Financials
13.3.1.4. Market Developments
13.3.1.5. Market Strategy
13.3.2. Thermo Fisher Scientific Inc.
13.3.3. Abbott Laboratories
13.3.4. Genome Diagnostics Pvt. Ltd.
13.3.5. InBios International, Inc.
13.3.6. ZeptoMetrix
13.3.7. Oscar Medicare Pvt Ltd.
13.3.8. Coris BioConcept
13.3.9. Omega Diagnostics Group PLC
13.3.10. DiaSys Diagnostic Systems GmbH
13.3.11. Others
14. Appendix
14.1. Research Methodology
14.2. Research Assumptions
14.3. Acronyms and Abbreviations